The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.5, a high estimate of $10.00, ...

As recently as last month, Lexicon Pharmaceuticals Inc. was holding out hope regarding the NDA for Zynquista (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 ...

Lexicon Pharmaceuticals (NASDAQ:LXRX) said the FDA has declined to approve its drug Zynquista, also known as sotagliflozin, ...

周四，H.C. Wainwright重申了对Lexicon Pharmaceuticals (NASDAQ:LXRX)的买入评级和$4.00的目标股价，相较于当前$0.89的价格有显著上涨空间。该股票近一周表现强劲，涨幅达36.91%。

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 53.33% ...

Lexicon Pharmaceuticals received a complete response letter from the Food and Drug Administration for its treatment of type 1 diabetes and chronic kidney disease.

The FDA rejected sotagliflozin for type 1 diabetes and CKD. Lexicon will focus on LX9211 for diabetic neuropathic pain, with ...

Lexicon Pharmaceuticals received a complete response letter from the Food and Drug Administration for its treatment of type 1 diabetes and chronic kidney disease. The FDA's response, which according ...

THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug ...

The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.